A NEXT-GENERATION TETRACYCLINE

WITH BROAD-SPECTRUM ACTIVITY, INCLUDING CERTAIN RESISTANT PATHOGENS1,2

See how NUZYRA works to overcome tetracycline resistance1

NUZYRA was designed to overcome the most common mechanisms of tetracycline resistance1,3,4:

Active efflux pumps

Ribosomal protection proteins

Clinical and in vitro activity against select1,2:

Gram-positives

Gram-negatives

Atypicals

Drug-resistant strains

MRSA

Methicillin-resistant Staphylococcus aureus1

In ABSSSI clinical infections and in vitro

SP

Streptococcus pneumoniae

In CABP clinical infections and in vitro

  • Macrolide resistant
  • Penicillin resistant (in vitro only)
  • Tetracycline resistant

VRE*

Vancomycin-resistant Enterococcus faecium1

In vitro only

  1. *The safety and effectiveness of NUZYRA in treating clinical infections due to this microorganism have not been established.1

Activity against common pathogens
See more antimicrobial activity for NUZYRA

DETAILS HERE

Prescribe once-daily* NUZYRA

A NEXT-GENERATION TETRACYCLINE

WITH

BROAD-SPECTRUM ACTIVITY

INCLUDING CERTAIN RESISTANT PATHOGENS

THAT MAY BE
APPROPRIATE TO

PRESCRIBE EMPIRICALLY

FOR ADULT PATIENTS WITH CABP OR ABSSSI1,2

*For treatment of CABP, the oral loading dose is 300 mg twice on Day 1.1

May help in patients with treatment complexities

ALTERNATIVE FOR PATIENTS WITH CERTAIN ALLERGIES1
  • NUZYRA may be an antibiotic treatment option for appropriate adult patients who have beta-lactam, fluoroquinolone, or sulfonamide hypersensitivities
  • NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients
LIMITED DRUG-DRUG INTERACTIONS1
  • NUZYRA is not expected to interact with drugs metabolized by cytochrome P450 enzymes
  • Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA
  • Absorption of oral tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations
NO DOSAGE ADJUSTMENT REQUIRED FOR PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT1